A potential dual protection vaccine: Recombinant feline herpesvirus-1 expressing feline parvovirus VP2 antigen

Recently, herpesvirus viral vectors that stimulate strong humoral and cellular immunity have been demonstrated to be the most promising platforms for the development of multivalent vaccines, because they contain various nonessential genes and exhibit long -life latency characteristics. Previously, we showed that the feline herpesvirus-1 (FHV-1) mutant WH2020-ATK/gI/gE, which was safe for felines and provided efficacious protection against FHV-1 challenge, can be used as a vaccine vector. Moreover, previous studies have shown that the major neutralizing epitope VP2 protein of feline parvovirus (FPV) can elicit high levels of neutralizing antibodies. Therefore, to develop a bivalent vaccine against FPV and FHV-1, we first generated a novel recombinant virus by CRISPR/Cas9-mediated homologous recombination, WH2020-ATK/gI/gE-VP2, which expresses the VP2 protein of FPV. The growth characteristics of WH2020-ATK/gI/gE-VP2 were similar to those of WH2020-ATK/gI/gE, and WH2020-ATK/gI/gE-VP2 was stable for at least 30 generations in CRFK cells. As expected, we found that the felines immunized with WH2020-ATK/gI/gE-VP2 produced FPV-neutralizing antibody titers (27.5) above the positive cutoff (26) on day 14 after single inoculation. More importantly, recombinant WH2020-ATK/gI/gE-VP2 exhibited severely impaired pathogenicity in inoculated and cohabiting cats. The kittens immunized with WH2020-ATK/gI/gE and WH2020-ATK/gI/gE-VP2 produced similar levels of FHV-specific antibodies and IFN-8. Furthermore, felines immunized with WH2020-ATK/gI/gE-VP2 were protected against challenge with FPV and FHV-1. These data showed that WH2020-ATK/gI/gE-VP2 appears to be a potentially safe, effective, and economical bivalent vaccine against FPV and FHV-1 and that WH2020-ATK/gI/gE can be used as a viral vector to develop feline multivalent vaccines.